Loading
Life sciences · Journal article
Journal of Periodontal Research · August 17, 2026
Raises a question worth testing. It does not answer one.
This narrative review synthesizes epidemiological evidence linking periodontitis to multiple chronic liver diseases (MASLD, NAFLD, viral hepatitis, cirrhosis, hepatocellular carcinoma) and proposes mechanistic pathways involving periodontal dysbiosis, systemic inflammation, and microbial translocation via an oral-gut-liver axis. However, the authors acknowledge that independent causal contributions of periodontitis remain unclear, and evidence for periodontal therapy improving liver disease outcomes is limited.
Journal article. Patients with chronic liver diseases and periodontitis; no specific trial population enrolled.
Epidemiologic studies link periodontitis with metabolic dysfunction-associated steatotic liver disease, nonalcoholic fatty liver disease, viral hepatitis, cirrhosis, and hepatocellular carcinoma Many associations persist after adjustment for shared risk factors (obesity, diabetes, smoking, nutritional status, socioeconomic factors), but independent contribution of periodontitis remains unclear Periodontal pathogens and virulence factors promote systemic inflammation, endotoxemia, microbial translocation, and immune dysregulation
Safety was not reported in the material analysed. Check the source before drawing any conclusion about harm.
This review supports integrated dental-medical care but does not establish that periodontal treatment changes liver disease outcomes. Clinicians should recognize the oral-hepatic axis as a hypothesis requiring further investigation rather than a basis for altering current practice.
This is a narrative review synthesizing epidemiological associations and mechanistic pathways; it raises questions about causality rather than answering them, as the authors explicitly state causal relationships remain to be established.
This review supports integrated dental-medical care but does not establish that periodontal treatment changes liver disease outcomes. Clinicians should recognize the oral-hepatic axis as a hypothesis requiring further investigation rather than a basis for altering current practice.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
What is missing. This record has no reported figures. That is a gap in the analysis, not a judgement about the study.
Chronic liver diseases and periodontitis are prevalent inflammatory disorders that impose substantial global health and economic burdens. Increasing evidence supports an oral-hepatic axis through which periodontal dysbiosis and chronic oral inflammation may influence hepatic homeostasis and disease progression. Epidemiologic studies have linked periodontitis with metabolic dysfunction-associated steatotic liver disease (MASLD), nonalcoholic fatty liver disease (NAFLD), viral hepatitis, cirrhosis, and hepatocellular carcinoma. Although many associations persist after adjustment for shared risk factors, including obesity, diabetes, smoking, nutritional status, and socioeconomic factors, the independent contribution of periodontitis to liver disease remains unclear. Experimental and translational studies indicate that periodontal pathogens and their virulence factors promote systemic inflammation, endotoxemia, microbial translocation, immune dysregulation, and alterations in gut microbial ecology. Nutritional factors may further influence these interactions through their effects on host immunity, inflammation, and microbial communities. Together, these mechanisms converge along the oral-gut-liver axis to activate hepatic inflammatory, oxidative stress and profibrotic pathways that contribute to steatosis, immune activation, and fibrogenesis. Emerging evidence suggests that trained immunity, driven by metabolic and epigenetic reprogramming, may represent an additional mechanism linking periodontitis and liver disease warranting future studies. Preliminary studies indicate that periodontal therapy may reduce systemic inflammatory burden and improve hepatic biomarkers; however, evidence for an effect on liver disease progression or clinical outcomes remains limited. Similarly, hepatic dysfunction may exacerbate immune dysregulation and periodontal breakdown, reinforcing an inflammatory loop. However, overall causal relationships remain to be established. This review summarizes current epidemiological, clinical, and mechanistic evidence linking periodontitis and chronic liver diseases, highlighting the oral-gut-liver axis, shared immunometabolic and nutritional pathways. Understanding these interactions shows the significance of integrated dental-medical care and opens new avenues for prevention and adjunctive therapy to sustain oral and hepatic health.
Taken from the source record, never inferred. Follow any of these and new work involving them reaches your briefing.